Furthermore, in a randomized phase 3 clinical study for recurrent/metastatic HNSCC, TPS-and CPS-PD-L1 positive was employed as a predictor of responses to PD-1/PD-L1 inhibitors [74, 75]. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.